KalVista Pharmaceuticals, Inc.

NasdaqGM:KALV Stock Report

Market Cap: US$533.3m

KalVista Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:KALV Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
28 Mar 24SellUS$14,905,154TCG Crossover Management, LLCCompany1,355,014US$11.00
20 Feb 24BuyUS$999,988Frazier Life Sciences Management, LPCompany65,573US$15.25
16 Feb 24SellUS$13,151,726TCG Crossover Management, LLCCompany877,125US$16.22
14 Feb 24SellUS$598,661Christopher YeaIndividual39,886US$15.01
14 Feb 24SellUS$422,827Edward FeenerIndividual28,171US$15.01
14 Feb 24SellUS$875,883Thomas CrockettIndividual58,356US$15.01
14 Feb 24SellUS$613,205Benjamin PalleikoIndividual40,855US$15.01
08 Feb 24BuyUS$1,257,829VR Adviser, LLCCompany86,048US$14.74
30 Jan 24BuyUS$1,274,793VR Adviser, LLCCompany88,099US$14.47
25 Jan 24BuyUS$89,492VR Adviser, LLCCompany7,030US$12.73
24 Jan 24BuyUS$1,241,685VR Adviser, LLCCompany99,129US$12.55
19 Jan 24BuyUS$1,801,602VR Adviser, LLCCompany143,605US$12.60
16 Jan 24BuyUS$333,779VR Adviser, LLCCompany26,246US$12.73
10 Jan 24BuyUS$1,726,457VR Adviser, LLCCompany137,700US$12.67
04 Jan 24BuyUS$720,543VR Adviser, LLCCompany59,369US$12.20
29 Dec 23BuyUS$6,465,650VR Adviser, LLCCompany519,017US$12.50
12 Dec 23BuyUS$2,972,278Frazier Life Sciences Management, LPCompany343,435US$9.53

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of KALV?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders704,2821.44%
Hedge Funds6,492,00513.2%
VC/PE Firms9,937,59820.2%
Institutions31,944,66265.1%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 25.6%.

Top Shareholders

Top 25 shareholders own 101.99% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
14.5%
VR Adviser, LLC
6,249,731US$77.1m0%2.54%
9.76%
Tang Capital Management, LLC
4,218,829US$52.1m2.27%3.7%
9.7%
Suvretta Capital Management, LLC
4,192,005US$51.7m0%1.55%
8.53%
Frazier Life Sciences Management, LP
3,687,867US$45.5m0%1.54%
7.47%
Capital Research and Management Company
3,227,620US$39.8m120%no data
6.81%
BlackRock, Inc.
2,945,116US$36.3m21.1%no data
5.32%
Vestal Point Capital, LP
2,300,000US$28.4m251%1.55%
4.74%
Adage Capital Management, L.P.
2,050,000US$25.3m-20.4%0.04%
4.61%
The Vanguard Group, Inc.
1,990,588US$24.6m18.1%no data
3.68%
Tavistock Life Sciences
1,590,000US$19.6m0%0.8%
3.1%
Great Point Partners, LLC
1,338,568US$16.5m0%2.54%
2.71%
Emerald Advisers, LLC
1,173,262US$14.5m-2.27%0.26%
2.61%
Saturn V Capital Management LP
1,128,478US$13.9m-21.7%3.99%
2.45%
First Turn Management, LLC
1,059,540US$13.1m-10.2%1.66%
2.04%
BioImpact Capital LLC
881,937US$10.9m15.9%1.37%
1.87%
Dafna Capital Management, LLC
806,973US$10.0m0%1.91%
1.87%
Geode Capital Management, LLC
806,271US$9.9m23.7%no data
1.75%
State Street Global Advisors, Inc.
756,430US$9.3m27.3%no data
1.7%
StemPoint Capital LP
736,765US$9.1m-36.5%2.08%
1.3%
Silverarc Capital Management, LLC
560,883US$6.9m-0.05%1.38%
1.24%
Driehaus Capital Management LLC
535,717US$6.6m-1.07%0.03%
1.24%
Dimensional Fund Advisors LP
534,979US$6.6m-7.71%no data
1.16%
Perceptive Advisors LLC
500,000US$6.2m0%0.11%
1.08%
Schroder Investment Management Limited
467,998US$5.8m83.7%no data
0.78%
Rosalind Advisors, Inc.
337,985US$4.2m17.4%2.33%